商业化能力卓越，创新转型迎业绩长周期增长 [Table_CoverStock] —康哲药业(0867.HK)公司首次覆盖报告 [Table_ReportDate] 2026 年 2 月 24 日 [Table_CoverAuthor] 唐爱金 医药行业首席分析师 S1500523080002 tangaijin@cindasc.com 证券研究报告 公司研究 [Table_ReportType] 公司首次覆盖报告 [Table_StockAndRank] 康哲药业(0867.HK) 投资评级 买入 上次评级 [Table_Chart] -40% -20% 0% 20% 40% 60% 80% 100% 康哲药业 恒生综合指数 资料来源：iFinD，信达证券研发中心 [Table_BaseData] 公司主要数据 | 收盘价（港元） | 15.44 | | --- | --- | | 52 周内股价波动区间(港元) | 7.15-15.45 | | 最近一月涨跌幅(％) | 13.03% | | 总股本(亿股) | 24.40 | | 流通股比例(％) | 100% | | 总市值(亿港元) | 376.66 ...

Core Viewpoint - 康哲药业 plans to spin off its skin health subsidiary, 德镁医药, for independent listing on the Hong Kong Stock Exchange, allowing shareholders to receive shares through a distribution method without new stock issuance [1][5] Company Overview - 德镁医药 focuses on skin health, offering comprehensive solutions for skin diseases such as psoriasis, vitiligo, atopic dermatitis, and acne, with a strong competitive edge in addressing unmet clinical needs [2][3] - 康哲药业 will concentrate on its core areas, including cardiovascular, central nervous system, digestive, and ophthalmic specialties, optimizing its asset structure post-spin-off [4][5] Market Potential - The skin disease treatment and care market in China is projected to reach RMB 764 billion in 2023, with a compound annual growth rate of 10.6% from 2023 to 2035, indicating significant growth potential for 德镁医药 [3] - 德镁医药's product pipeline includes competitive offerings such as JAK1/2 topical cream and IL-23 monoclonal antibody injection, supported by a commercial team of over 650 professionals [3] Strategic Benefits - The spin-off is expected to enhance both 康哲药业 and 德镁医药's market positions, allowing for independent fundraising and improved operational efficiency [1][4] - The separation will enable 德镁医药 to establish its own valuation system, potentially unlocking greater growth opportunities and attracting investors [5]